Entities / Company
BioMarin Pharmaceutical.
American company
- Reports this week
- 1
- Active events
- 1
- Connections
- 95
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
Earlier this month
One to three months ago
-
BioMarin Pharmaceutical acquired Amicus, contributing to Q2 revenue growth.Some support4 reports
-
BioMarin Pharmaceutical filed a report with the Securities and Exchange Commission on July 24, 2026.Some support3 reports
-
BioMarin Pharmaceutical stock received updates on July 18, 2026, including a price target boost from Citigroup, reported by Benzinga.Some support4 reports
-
Truist Financial upgraded BioMarin Pharmaceutical to strong-buy, and Morgan Stanley lowered its target price on the company's stock.Some support2 reports
Gone quiet
No new reports in 90+ days-
BioMarin Pharmaceutical acquired Inozyme Pharma, Inc. on June 21, 2025.Some support5 reports
-
Trump pledged to unleash American oil and gas, leading to discussion of BioMarin Pharmaceutical's prospects through the lens of Benjamin Graham's investment philosophy.Some support3 reports1 development inside
-
BioCryst Pharmaceuticals is noted as benefiting from Trump-era tariffs on September 2, 2025.Some support4 reports1 development inside
-
Geode Capital Management raised its stake in BioMarin Pharmaceutical on June 18, 2026.Some support1 report
-
Ian Clark served as CEO of Genentech and was appointed to the BioMarin Pharmaceutical Board of Directors.Some support1 report
-
Barclays initiated a Buy rating on BioMarin Pharmaceutical, noting the company benefits from Trump-era tariffs.Speculative1 report
-
TD Cowen analysts questioned about revenue decline, while Goldman Sachs inquired about business development.Speculative1 report
-
BioMarin Pharmaceutical's product, valoctocogene roxaparvovec, is under scrutiny as analysts suggest AI stocks offer greater upside potential.Speculative2 reports
-
Morgan Stanley initiated coverage on July 11, 2025, with a Buy rating, noting that Voxzogo is BioMarin's therapy for achondroplasia and that TransCon CNP could be a competitor.Some support1 report
-
BioMarin Pharmaceutical develops therapies for rare genetic disorders.Some support1 report
-
Analysts set price targets for BioMarin Pharmaceutical stock on July 16, 2025.Some support2 reports
-
Alexander Hardy was appointed as the CEO of BioMarin Pharmaceutical.Some support1 report
-
Biogen's strong results hint at market expectations for BioMarin, positioning them as peers in the therapeutics segment.Some support3 reports
-
Automated Insights generated a story using company data related to BioMarin Pharmaceutical on August 5, 2025.Some support1 report
-
Bio-Techne, West Pharmaceutical Services, and BioMarin Pharmaceutical operate within the pharmaceutical supply chain, with WST providing packaging for injectable drugs.Some support1 report
-
Leerink Partners reiterated a Buy rating on BioMarin Pharmaceutical on August 12, 2025.Some support2 reports
-
BioMarin Pharmaceutical leadership stated on August 13, 2025, that the company is experiencing robust demand for its key therapies and noted an increase in net new U.S. patients.Some support1 report
-
BioMarin Pharmaceutical's stock fell while the S&P 500 climbed on August 20, 2025.Some support2 reports
-
Barclays maintained a Buy rating on BioMarin Pharmaceutical on August 23, 2025.Some support1 report
-
BioMarin Pharmaceutical is based in San Rafael, California.Some support4 reports
No events began in the chosen period. Widen it, or reset.
Around BioMarin Pharmaceutical this week
News at the entities that move BioMarin Pharmaceutical most-
Brian Mueller StructuralEric Fields addresses construction industry workforce shortages, while Brian Mueller comments on Arizona's long-term economic growth.Moves BioMarin Pharmaceutical
-
Morgan Stanley Mentioned togetherFinancial firms including Morgan Stanley, Truist Financial, Jefferies Financial Group, and CIBC issued rating and price objective updates for Clearway Energy.Moves BioMarin Pharmaceutical
-
Truist Financial Mentioned togetherMarketBeat aggregates data on Inventiva's stock, and Truist Financial has started coverage of the company.Moves BioMarin Pharmaceutical
-
Securities and Exchange Commission StructuralBlackRock, the manager of the iShares Core MSCI EAFE ETF, has made required filings with the Securities and Exchange Commission regarding institutional holdings.Moves BioMarin Pharmaceutical
-
Geode Capital Management TransactionalGeode Capital Management increased its stake in Amgen stock and filed the disclosure with the SEC.Moves BioMarin Pharmaceutical
-
Benzinga Mentioned togetherBenzinga reported on the recent stock price activity of SpaceX.Moves BioMarin Pharmaceutical
Connections
The 19 strongest of 95, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Amicus Therapeutics Structural
BioMarin acquired Amicus Therapeutics, establishing a parent-subsidiary relationship and integrating its products.
-
Amicus Structural
BioMarin acquired Amicus, establishing a structural relationship where Amicus's operations support BioMarin's revenue growth.
-
SEC Structural
BioMarin operates as a company under the formal regulatory oversight of the U.S. Securities and Exchange Commission.
-
Brian Mueller Structural
Brian Mueller serves as the Chief Financial Officer of BioMarin Pharmaceutical.
-
Securities and Exchange Commission Structural
BioMarin Pharmaceutical is subject to regulatory oversight and filing requirements by the Securities and Exchange Commission.
-
Truist Financial Mentioned together
Truist Financial upgraded BioMarin Pharmaceutical to a strong-buy rating.
-
valoctocogene roxaparvovec Structural
BioMarin Pharmaceutical is the developer and presenter of data regarding the product valoctocogene roxaparvovec.
-
Morgan Stanley Mentioned together
Morgan Stanley provides market analysis and target price recommendations for BioMarin Pharmaceutical stock.
Show all 19 connections
-
Geode Capital Management Transactional
Geode Capital Management raised its stake in BioMarin Pharmaceutical.
-
Amgen Operational
The two companies actively compete within the therapeutics segment of the biopharmaceutical market.
-
Applied DNA Sciences Operational
Both companies are actively competing against each other within the broader healthcare market and are frequently compared by investors.
-
Benzinga Mentioned together
Benzinga provides financial reporting and stock price targets for BioMarin Pharmaceutical.
-
Biogen Mentioned together
The companies are co-mentioned as peers operating within the competitive therapeutics segment.
-
Nasdaq Shared context
BioMarin Pharmaceutical's stock is listed and traded on the Nasdaq exchange.
-
MarketBeat Mentioned together
MarketBeat collects and reports on professional market sentiment regarding BioMarin Pharmaceutical.
-
Citigroup Mentioned together
Citigroup provides market coverage and rating updates for BioMarin stock.
-
San Rafael Shared context
BioMarin Pharmaceutical is located in San Rafael.
-
Joseph Schwartz Mentioned together
The provided evidence only discusses BioMarin Pharmaceutical and does not mention Joseph Schwartz.
-
Bank of America Mentioned together
No evidence was provided to establish a relationship between Bank of America and BioMarin Pharmaceutical.
History
Events by the month they beganSeptember 2026
3 events- Investors are comparing the financial performance metrics of BioMarin Pharmaceutical and Metagenomi.
- MarketBeat aggregated analyst recommendations and price targets for BioMarin Pharmaceutical and Abeona Therapeutics Inc.
- Applied DNA Sciences and BioMarin Pharmaceutical are identified as competing companies within the healthcare market.
August 2026
1 eventJuly 2026
3 events- BioMarin Pharmaceutical filed a report with the Securities and Exchange Commission on July 24, 2026.
- BioMarin Pharmaceutical stock received updates on July 18, 2026, including a price target boost from Citigroup, reported by Benzinga.
- Truist Financial upgraded BioMarin Pharmaceutical to strong-buy, and Morgan Stanley lowered its target price on the company's stock.
Show 1 earlier month
June 2026
20 events- BioMarin Pharmaceutical acquired Inozyme Pharma, Inc. on June 21, 2025.
- Trump pledged to unleash American oil and gas, leading to discussion of BioMarin Pharmaceutical's prospects through the lens of Benjamin Graham's investment philosophy.
- BioCryst Pharmaceuticals is noted as benefiting from Trump-era tariffs on September 2, 2025.
- Geode Capital Management raised its stake in BioMarin Pharmaceutical on June 18, 2026.
- Ian Clark served as CEO of Genentech and was appointed to the BioMarin Pharmaceutical Board of Directors.
- Barclays initiated a Buy rating on BioMarin Pharmaceutical, noting the company benefits from Trump-era tariffs.
- TD Cowen analysts questioned about revenue decline, while Goldman Sachs inquired about business development.
- BioMarin Pharmaceutical's product, valoctocogene roxaparvovec, is under scrutiny as analysts suggest AI stocks offer greater upside potential.
- Morgan Stanley initiated coverage on July 11, 2025, with a Buy rating, noting that Voxzogo is BioMarin's therapy for achondroplasia and that TransCon CNP could be a competitor.
- BioMarin Pharmaceutical develops therapies for rare genetic disorders.
- Analysts set price targets for BioMarin Pharmaceutical stock on July 16, 2025.
- Alexander Hardy was appointed as the CEO of BioMarin Pharmaceutical.
- Biogen's strong results hint at market expectations for BioMarin, positioning them as peers in the therapeutics segment.
- Automated Insights generated a story using company data related to BioMarin Pharmaceutical on August 5, 2025.
- Bio-Techne, West Pharmaceutical Services, and BioMarin Pharmaceutical operate within the pharmaceutical supply chain, with WST providing packaging for injectable drugs.
- Leerink Partners reiterated a Buy rating on BioMarin Pharmaceutical on August 12, 2025.
- BioMarin Pharmaceutical leadership stated on August 13, 2025, that the company is experiencing robust demand for its key therapies and noted an increase in net new U.S. patients.
- BioMarin Pharmaceutical's stock fell while the S&P 500 climbed on August 20, 2025.
- Barclays maintained a Buy rating on BioMarin Pharmaceutical on August 23, 2025.
- BioMarin Pharmaceutical is based in San Rafael, California.